Merck & Co., Inc. $MRK Shares Sold by Agate Pass Investment Management LLC

Agate Pass Investment Management LLC lowered its position in Merck & Co., Inc. (NYSE:MRKFree Report) by 51.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,840 shares of the company’s stock after selling 7,325 shares during the quarter. Agate Pass Investment Management LLC’s holdings in Merck & Co., Inc. were worth $541,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Barnes Dennig Private Wealth Management LLC acquired a new position in Merck & Co., Inc. in the 1st quarter worth $27,000. Legend Financial Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at about $25,000. CBIZ Investment Advisory Services LLC raised its stake in shares of Merck & Co., Inc. by 141.7% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 377 shares of the company’s stock valued at $34,000 after purchasing an additional 221 shares in the last quarter. MorganRosel Wealth Management LLC acquired a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at about $36,000. Finally, Fiduciary Wealth Partners LLC acquired a new stake in shares of Merck & Co., Inc. in the 1st quarter valued at about $48,000. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $86.02 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $111.58. The firm has a 50-day simple moving average of $83.47 and a 200 day simple moving average of $81.51. The company has a market cap of $214.87 billion, a PE ratio of 13.25, a P/E/G ratio of 0.90 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The business had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th were given a $0.81 dividend. The ex-dividend date was Monday, September 15th. This represents a $3.24 annualized dividend and a yield of 3.8%. Merck & Co., Inc.’s dividend payout ratio is 49.92%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Wells Fargo & Company cut their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 30th. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday. Morgan Stanley cut their target price on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Finally, Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and cut their target price for the company from $100.00 to $90.00 in a research note on Wednesday, September 17th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Hold” and an average target price of $104.31.

View Our Latest Stock Report on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Recommended Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.